Amgen (AMGN) EBITDA (2009 - 2026)

Amgen (AMGN) has reported EBITDA for 18 consecutive years, with $2.7 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA rose 126.32% year-over-year to $2.7 billion; the TTM figure through Mar 2026 stood at $10.6 billion (up 41.95% YoY), while the FY2025 annual figure was $9.1 billion, up 25.1% from the prior year.
• EBITDA came in at $2.7 billion for Q1 2026 at Amgen, down from $2.7 billion in the prior quarter.
• The five-year high for EBITDA was $2.7 billion in Q4 2025, with the low at $991.0 million in Q1 2024.
• Average EBITDA over 5 years is $2.1 billion, with a median of $2.2 billion recorded in 2022.
• Across the five-year window, EBITDA jumped 162.8% in 2022 and plunged 48.41% in 2024, its largest moves.
• Year by year, EBITDA stood at $2.2 billion in 2022, then slumped by 43.0% to $1.3 billion in 2023, then soared by 81.83% to $2.3 billion in 2024, then climbed by 17.7% to $2.7 billion in 2025, then dropped by 1.99% to $2.7 billion in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $2.7 billion, $2.7 billion, and $2.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.